A Meta-analysis on the Effectiveness of Extracellular Vesicles as Nanosystems for Targeted Delivery of Anticancer Drugs

Abstract

While the efficacy of anticancer drugs is hampered by low bioavailability and systemic toxicity, the uncertainty remains whether encapsulation of these drugs into natural nanovesicles such as extracellular vesicles (EVs) could improve controlled drug release and efficacy for targeted tumor therapy. Thus, we performed a metaanalysis for studies reporting the efficacy of EVs as nanosystems to deliver drugs and nucleic acid, protein, and virus (NPV) to tumors using the random-effects model. The electronic search of articles was conducted through Cochrane, PubMed, Scopus, Science Direct, and Clinical Trials Registry from inception up till September 2022. The pooled summary estimate and 95% confidence interval of tumor growth inhibition, survival, and tumor targeting were obtained to assess the efficacy. The search yielded a total of 119 studies that met the inclusion criteria having only 1 clinical study. It was observed that the drug-loaded EV was more efficacious than the free drug in reducing tumor volume and weight with the standardized mean difference (SMD) of −1.99 (95% CI:

Engineering Approaches for Exosome Cargo Loading and Targeted Delivery: Biological versus Chemical Perspectives

“…For example, chemical molecules such as doxorubicin (DOX) and paclitaxel (PAC) are commonly enclosed through incubation and sonication, whereas genetic materials like miRNA and siRNA are enclosed through transfection and electroporation. 34 Moreover, the loading efficiency is significantly affected by the hydrophobic nature of the drug given the hydrophilic nature of the exosome core.…”

Recent Trends in the Use of Small Extracellular Vesicles as Optimal Drug Delivery Vehicles in Oncology

“…Analysis of 119 animal studies and 1 clinical study indicated marked reductions in tumor growth and improved survival rates with sEVencapsulated drugs compared to free drugs. 83 Precise drug localization at the tumor site underscores the effectiveness of sEVs as secure and efficient nanoplatforms.…”

CD81-guided heterologous EVs present heterogeneous interactions with breast cancer cells

“…Recent seminal studies highlighted the EV potential in delivering siRNAs, small molecules, and microRNAs (Möller and Lobb, 2020). Through surface engineering and cargo loading techniques, EVs were reported to exert anti-inflammatory and antitumor effects, or neuroprotection and tissue regeneration (Muhammad et al, 2023) , (Roudi et al, 2023) , (Greening et al, 2023).…”